Nature Communications (May 2019)
A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML
- Christina D. Drenberg,
- Anang Shelat,
- Jinjun Dang,
- Anitria Cotton,
- Shelley J. Orwick,
- Mengyu Li,
- Jae Yoon Jeon,
- Qiang Fu,
- Daelynn R. Buelow,
- Marissa Pioso,
- Shuiying Hu,
- Hiroto Inaba,
- Raul C. Ribeiro,
- Jeffrey E. Rubnitz,
- Tanja A. Gruber,
- R. Kiplin Guy,
- Sharyn D. Baker
Affiliations
- Christina D. Drenberg
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Anang Shelat
- Department of Chemical Biology and Therapeutics, St. Jude Children’s Research Hospital
- Jinjun Dang
- Department of Oncology, St. Jude Children’s Research Hospital
- Anitria Cotton
- Department of Oncology, St. Jude Children’s Research Hospital
- Shelley J. Orwick
- Comprehensive Cancer Center, The Ohio State University
- Mengyu Li
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Jae Yoon Jeon
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Qiang Fu
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Daelynn R. Buelow
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Marissa Pioso
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Shuiying Hu
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- Hiroto Inaba
- Department of Oncology, St. Jude Children’s Research Hospital
- Raul C. Ribeiro
- Department of Oncology, St. Jude Children’s Research Hospital
- Jeffrey E. Rubnitz
- Department of Oncology, St. Jude Children’s Research Hospital
- Tanja A. Gruber
- Department of Oncology, St. Jude Children’s Research Hospital
- R. Kiplin Guy
- Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky
- Sharyn D. Baker
- Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University
- DOI
- https://doi.org/10.1038/s41467-019-09917-0
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 16
Abstract
Pediatric AML is traditionally treated with chemotherapy and stem cell transplant but some subsets of patients have a poor response to therapy. Here, the authors perform a high throughput screen and identify several FDA approved drugs that might be useful in treating this disease.
